Skip to main content
SpringerLink
Log in

Normal Tissue TNM Toxicity Taxonomy

Scoring the Adverse Effects of Cancer Treatment

  • Chapter
Late Effects of Cancer Treatment on Normal Tissues

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 998 Accesses

Abstract

Philosophically, the TNM Cancer Classification is based on the premise that all malignant tumors have a similar life cycle. Cancers originate in a normal tissue, then spread regionally into lymph nodes and then to systematic distant sites hematogenously. In a parallel fashion, the conceptual design of a normal tissue TNM classification is based on a similarity of normal tissue injury following multimodal cancer treatment which is often greatest in the structure/organ of cancer origin and decreases in neighboring normal tissues. There may be a generalized or systemic toxicity. NT = The normal Tissue, anatomic structure, organ in which the cancer arose and spreads initially. NN = Neighboring or surrounding normal tissues or organs, viscera that are not involved by the tumor but in the regional nodal drainage zone. NM = SysteMic effects that are generalized and include hematologic, hepatic toxicity, weight loss.

former Associate Director of the James P. Wilmot Cancer Center, and former Associate in the Department of medicine and Surgery

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Cancer Society (1995) Cancer Facts and Figures 1995. Atlanta, American Cancer Society

    Google Scholar 

  2. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  PubMed  CAS  Google Scholar 

  3. Trotti A, Byhardt R, Stetz J et al (2000) Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13–47

    Article  PubMed  CAS  Google Scholar 

  4. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346

    Article  PubMed  CAS  Google Scholar 

  5. Trotti A (2002) The evolution and application of toxicity criteria. Sem Radiat Oncol 12:1–3

    Article  Google Scholar 

  6. Rubin P, Constine S, Fajardo L et al (1995) Overview of Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys31:1041–1042

    Article  PubMed  CAS  Google Scholar 

  7. Trotti A, Rubin P (2003) Introduction. Sem Radiat Oncol 13:175

    Article  Google Scholar 

  8. Trotti A, Colevas DA, Setser A et al (2003) CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181

    Article  PubMed  Google Scholar 

  9. Rubin P, Casarett GW (1968) Clinical Radiation Pathology. Philadelphia, PA, Saunders

    Google Scholar 

  10. Rubin P, Johnston CJ, Williams JP et al (1995) A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33:99–109

    Article  PubMed  CAS  Google Scholar 

  11. Fedyk ER, Jones D, Critchley HO et al (2001) Expression of stromal-derived factor-1 is decreased by IL-1 and TNF and in dermal wound healing. J Immunol 166:5749–5754

    PubMed  CAS  Google Scholar 

  12. Mercado AM, Padgett DA, Sheridan JF et al (2002) Altered kinetics of IL-1,I1-1, and KGF-1 gene expression in early wounds of restrained mice. Brain Behav Immun 16:150–162

    Article  PubMed  CAS  Google Scholar 

  13. Petak I, Houghton JA (2001) Shared pathways: Death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 7:95–106

    Article  PubMed  CAS  Google Scholar 

  14. Rubin P (2001) Clinical Oncology. 8th ed. Philadelphia, PA, WB Saunders

    Google Scholar 

  15. Bentzen SM, Dörr W, Anscher MS et al (2003) Normal tissue effects: reporting and analysis. Semin Radiat Oncol 13:189–202

    Article  PubMed  Google Scholar 

  16. Trotti A, Bentzen MS (2004) The need for adverse effects reporting standards in oncologyclinical trials. J Clinc Oncol 22:19–22

    Article  Google Scholar 

  17. Movsas B (2003) Quality of life in oncology trials: a clinical guide. Semin Radiat Oncol 13:189–202

    Article  Google Scholar 

  18. Peters LJ, Withers HR, Brown BW (1995) Complicating issues in complication reporting. Int J Radiat Oncol Biol Phys 31:1349–1351

    Article  PubMed  CAS  Google Scholar 

  19. Williams J, Chen Y, Rubin P, Finkelstein J, Okunieff P (2003) The biological basis of a comprehensive grading system for the adverse effects of cancer treatment. In: JE Tepper (ed) The adverse effects of cancer treatment: metrics, management, and investigations. Semin Radiat Oncol 13:182–188

    Google Scholar 

  20. World Health Organization (1992) ICD 10: international statistical classification of diseases and related health problems, 10th ed. American Psychiatric Publishing

    Google Scholar 

  21. American Joint Committee on Cancer (AJCC) (2002) Cancer staging manual, 6th ed. Springer, Berlin Heidelberg New York

    Google Scholar 

  22. Federative Committee on Anatomical Terminology (FCAT) (1998) Terminologia anatomica: international anatomical terminology. Georg Thieme Verlag, Stuttgart

    Google Scholar 

  23. Davidson SE, Burns MP, Routledge JA et al (2003) Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and the Franco-Italian glossary. Radiother Oncol 69:195–200

    Article  PubMed  Google Scholar 

  24. Davidson SE, Burns MP, Routledge JA et al (2003) The impact of radiotherapy for carcinoma of the cervix on sexual function assessed using the LENT SOMA scales. Radiother Oncol 68:241–247

    Article  PubMed  Google Scholar 

  25. Routledge JA, Burns MP, Swindell R et al (2003) Evaluation of the LENT-SOMA scales for the prospective assessment of treatment morbidity in cervical carcinoma. Int J Radiat Oncol Biol Phys 56:502–510

    Article  PubMed  Google Scholar 

  26. Hoeller U, Tribius S, Kuhlmey A et al (2003) Increasing the rate of late toxicity by changing the score? A comparison of RTOG/EORTC and LENT/SOMA scores. Int J Radiat Oncol Biol Phys 55:1013–1018

    Article  PubMed  Google Scholar 

  27. Fehlauer F, Tribius S, Holler U et al (2003) Long-term radiation sequelae after breast-conserving therapy in women with early-stage breast cancer: an observational study using the LENT-SOMA scoring system. Int J Radiat Oncol Biol Phys 55:651–658

    Article  PubMed  Google Scholar 

  28. Denis F, Garaud P, Bardet E et al (2003) Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55:93–98

    Article  PubMed  Google Scholar 

  29. Davidson SE, Burns M, Routledge J et al (2002) Short report: a morbidity scoring system for Clinical Oncology practice: questionnaires produced from the LENT SOMA scoring system. Clin Oncol (R Coll Radiol) 14:68–69

    CAS  Google Scholar 

  30. Anacak Y, Yalman D, Ozsaran Z et al (2001) Late radiation effects to the rectum and bladder in gynecologic cancer patients: the comparison of LENT/SOMA and RTOG/ EORTC late-effects scoring systems. Int J Radiat Oncol Biol Phys 50:1107–1112

    Article  PubMed  CAS  Google Scholar 

  31. Tawfiq N, Lagarde P, Stockle E et al (2000) Conservative treatment of extremity soft tissue sarcomas. Functional evaluation using LENT-SOMA scales and Enneking scoring. Cancer Radiother 4:421–427 (French)

    PubMed  CAS  Google Scholar 

  32. Bragg DG, Rubin P, Hricak H (2002) Oncologic imaging, 2nd ed. WB Saunders Company, Philadelphia

    Google Scholar 

  33. Husband JES, Reznek RH (1998) Imaging in oncology. ISIS Medical Media, Oxford

    Google Scholar 

  34. Fajardo LF, Berthrong M, Anderson RE (2001) Radiation pathology. Oxford University Press, USA, 2001

    Google Scholar 

  35. Movsas B, Scott C, Langer C et al (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol. 23(10):2145–2154

    Article  PubMed  CAS  Google Scholar 

  36. Forestiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 647, Rochester, NY, 14642, USA

    Philip Rubin MD (Professor and Chair Emeritus)

Authors
  1. Philip Rubin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 647, Rochester, NY, 14642, USA

    Philip Rubin MD (Professor Emeritus, Chair Emeritus) & Paul Okunieff MD (Philip Rubin Professor of Radiation Oncology, Chair) (Professor Emeritus, Chair Emeritus) &  (Philip Rubin Professor of Radiation Oncology, Chair)

  2. Department of Radiation Oncology, Departments of Radiation Oncology and Pediatrics, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 647, Rochester, NY, 14642, USA

    Louis S. Constine MD (Professor of Radiation Oncology and Pediatrics, Vice Chair) (Professor of Radiation Oncology and Pediatrics, Vice Chair)

  3. Department of Radiation Oncology, Duke University Medical Center, P.O. Box 3085, Durham, NC, 27710, USA

    Lawrence B. Marks MD (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Rubin, P. (2008). Normal Tissue TNM Toxicity Taxonomy. In: Rubin, P., Constine, L.S., Marks, L.B., Okunieff, P. (eds) Late Effects of Cancer Treatment on Normal Tissues. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-49070-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-49070-8_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-49069-2

  • Online ISBN: 978-3-540-49070-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation